Mumbai, Dec 21: Cadila Healthcare said that its wholly owned subsidiary Zydus Pharmaceuticals (USA) has received final
approval from the United States Food & Drug Administration (USFDA)
to market Nifedipine Extended-Release Tablets USP in strengths of 30
mg, 60 mg and 90 mg.
The drug is used to treat hypertension (high blood pressure)
and angina (chest pain). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04. UNI
The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04. UNI
Post A Comment:
0 comments so far,add yours